

Appl. Serial No. 10/646,256  
Amendment dated August 19, 2004  
Reply to Office Action mailed July 29, 2004


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-5 (canceled)

6. (original) A compound of the formula:



wherein

R<sub>1</sub> is a halogenated phenyl;

R<sub>2</sub> is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R<sub>3</sub> is NH<sub>2</sub>, OH or 2-amino-3-phenylpropanamide.


7. (original) The compound of Claim 6, wherein R<sub>1</sub> is 3,4-dichlorophenyl.
8. (original) The compound of Claim 6, wherein R<sub>1</sub> is 3-chlorophenyl.
9. (original) The compound of Claim 6, wherein R<sub>3</sub> is OH.
10. (original) The compound of Claim 6, wherein R<sub>3</sub> is 2-amino-3-phenylpropanamide.

Appl. Serial No. 10/646,256  
Amendment dated August 19, 2004  
Reply to Office Action mailed July 29, 2004

11. (original) A pharmaceutical composition comprising a compound of Claim 6 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

12-31 (cancelled)

32. (currently amended): A method of treating colon cancer for inhibiting protein prenylation comprising administering to a mammal in need of such treatment a therapeutically effective amount of contacting an isoprenoid transferase with a compound of the formula:



~~or a pharmaceutically-acceptable salt thereof~~, wherein

R<sub>1</sub> is a halogenated phenyl;

R<sub>2</sub> is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R<sub>3</sub> is NH<sub>2</sub>, OH or 2-amino-3-phenylpropanamide.

33. (original) The method of Claim 32, wherein R<sub>1</sub> is 3,4-dichlorophenyl.

34. (original) The method of Claim 32, wherein R<sub>1</sub> is 3-chlorophenyl.

35. (original) The method of Claim 32, wherein R<sub>3</sub> is OH.

36. (original) The method of Claim 32, wherein R<sub>3</sub> is 2-amino-3-phenylpropanamide.

37. (cancelled)

Appl. Serial No. 10/646,256  
Amendment dated August 19, 2004  
Reply to Office Action mailed July 29, 2004

38. (cancelled)

39. (original) The method of Claim 32, wherein said compound inhibits farnesyl-protein transferase.

40. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type I.

41. (original) The method of Claim 40, wherein said compound has an IC<sub>50</sub> value of about 60nM or less.

42. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type II.

43-62 (cancelled)